secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950170-23-004106
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports Q4 2022 net loss of $67.5M; cash ~$1B funds into 2025
--------------------------------------------------------------------------------

- Net loss per share $0.56 for Q4 2022, flat vs Q4 2021; full-year net loss $290.5M ($2.59/share).
- Cash, cash equivalents and investments ~$1.0B as of Dec 31, 2022, up from $958.1M year-end 2021.
- RLY-4008 interim data: 88% ORR at pivotal dose (70 mg) in FGFR2-fusion cholangiocarcinoma; registrational path set.
- Breast cancer portfolio: RLY-2608 monotherapy and combination arms ongoing; initial data expected H1 2023.
- Raised $300M gross proceeds in follow-on public offering; R&D expenses $246.4M for full year 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/0000950170-23-004106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/rlay-20230223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer